Reality Check on Bipolar Disorder
Market access for bipolar disorder treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 21% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In May 2021, the FDA approved Alkermes plc’s Lybalvi (olanzapine and samidorphan) for adults with schizophrenia and for adults with bipolar I disorder, for the acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate and as a maintenance monotherapy treatment
- Key Findings: Coverage is primarily under the pharmacy benefit, but medical coverage
is available for some medications. Coverage is restricted for most brand-name products
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.